Recon: NICE Backs Merck's Prevymis for CMV; China's Hansoh Pharma Eyes $1B IPO - Regulatory Focus

Recon: NICE Backs Merck's Prevymis for CMV; China's Hansoh Pharma Eyes $1B IPO  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Merck's R&D boss sees more promise in his big ...